Literature DB >> 24419062

Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.

Laurence Slama1, Xiuhong Li, Todd Brown, Lisa P Jacobson, Gilles Pialoux, Bernard Macatangay, Robert K Bolan, John Phair, Frank J Palella.   

Abstract

BACKGROUND: Antiretroviral therapy (ART) regimens changes occur frequently among HIV-infected persons. Duration and type of initial highly active antiretroviral therapy (HAART) and factors associated with regimen switching were evaluated in the Multicenter AIDS Cohort Study.
METHODS: Participants were classified according to the calendar period of HAART initiation: T1 (1996-2001), T2 (2002-2005), and T3 (2006-2009). Kaplan-Meier curves depicted time from HAART initiation to first regimen changes within 5.5 years. Cox proportional hazards regression models were used to examine factors associated with time to switching.
RESULTS: Of 1009 participants, 796 changed regimen within 5.5 years after HAART initiation. The percentage of participants who switched declined from 85% during T1 to 49% in T3. The likelihood of switching in T3 decreased by 50% (P < 0.01) compared with T1 after adjustment for pre-HAART ART use, age, race, and CD4 count. Incomplete HIV suppression decreased over time (P < 0.01) but predicted switching across all time periods. Lower HAART adherence (≤95% of prescribed doses) was predictive of switching only in T1. In T2, central nervous system symptoms predicted switching [relative hazard (RH) = 1.7; P = 0.012]. Older age at HAART initiation was associated with increased switching in T1 (RH = 1.03 per year increase) and decreased switching in T2 (RH = 0.97 per year increase).
CONCLUSIONS: During the first 15 years of the HAART era, initial HAART regimen duration lengthened and regimen discontinuation rates diminished. Both HIV RNA nonsuppression and poor adherence predicted switching before 2001 while side effects that were possibly ART related were more prominent during T2.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419062      PMCID: PMC3896869          DOI: 10.1097/QAI.0b013e3182a99a0d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  40 in total

1.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.

Authors:  T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

2.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

Review 3.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

4.  Could better tolerated HIV drug regimens improve patient outcome?

Authors:  Mikaela Smit; Colette Smit; Ide Cremin; Geoffrey P Garnett; Timothy Hallett; Frank de Wolf
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

5.  Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

Authors:  A Mocroft; M Youle; A Moore; C A Sabin; S Madge; A C Lepri; M Tyrer; C Chaloner; D Wilson; C Loveday; M A Johnson; A N Phillips
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

6.  Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

Authors:  Juan A Arnaiz; Josep Mallolas; Daniel Podzamczer; Jan Gerstoft; Jens D Lundgren; Pedro Cahn; Gerd Fätkenheuer; Antonella D'Arminio-Monforte; Arnaldo Casiró; Peter Reiss; David M Burger; Michael Stek; José M Gatell
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

7.  Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Authors:  L P Jacobson; R Li; J Phair; J B Margolick; C R Rinaldo; R Detels; A Muñoz
Journal:  Am J Epidemiol       Date:  2002-04-15       Impact factor: 4.897

8.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

Review 9.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

10.  Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study.

Authors:  Cynthia A Kleeberger; Jennifer Buechner; Frank Palella; Roger Detels; Sharon Riddler; Rebecca Godfrey; Lisa P Jacobson
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

View more
  11 in total

1.  Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.

Authors:  Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

2.  Cost considerations in the current antiretroviral era.

Authors:  Ellen F Eaton; Ashutosh Tamhane; Michael Saag; Michael J Mugavero; Meredith L Kilgore
Journal:  AIDS       Date:  2016-09-10       Impact factor: 4.177

3.  Increased Antiretroviral Therapy Use and Virologic Suppression in the Bronx in the Context of Multiple HIV Prevention Strategies.

Authors:  David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-17       Impact factor: 2.205

4.  Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).

Authors:  Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng
Journal:  Antivir Ther       Date:  2018

5.  Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011.

Authors:  Anandi N Sheth; Ighovwerha Ofotokun; Kate Buchacz; Carl Armon; Joan S Chmiel; Rachel L D Hart; Rose Baker; John T Brooks; Frank J Palella
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

6.  Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure.

Authors:  Ellen F Eaton; Ashutosh Tamhane; Thibaut Davy-Mendez; William C Mathews; Richard D Moore; Michael S Saag; Michael J Mugavero
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

Review 7.  Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy.

Authors:  Patrick G Clay; Rustin D Crutchley
Journal:  Infect Dis Ther       Date:  2014-11-12

8.  Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceive.

Authors:  Caiyun Liao; Maybel Wahab; Jean Anderson; Jenell S Coleman
Journal:  J Int AIDS Soc       Date:  2015-01-09       Impact factor: 5.396

9.  Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Authors:  Antonio Di Biagio; Alessandro Cozzi-Lepri; Roberta Prinapori; Gioacchino Angarano; Andrea Gori; Tiziana Quirino; Andrea De Luca; Andrea Costantini; Cristina Mussini; Giuliano Rizzardini; Antonella Castagna; Andrea Antinori; Antonella dʼArminio Monforte
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731

10.  Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research.

Authors:  Ellen F Eaton; Ashutosh R Tamhane; Greer A Burkholder; James H Willig; Michael S Saag; Michael J Mugavero
Journal:  Open Forum Infect Dis       Date:  2016-06-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.